Loading
NASDAQHealthcareBiotechnology
Latest quote
$21.6509
−$0.4391 · -1.99%
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
Regular session
$21.6509
−$0.4391 · -1.99%
Regular session · ET · Market data may be delayed.
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
Day range
Current $21.6509
52-week range
Current $21.6509
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
40
Expensive
Sentiment
40
Bearish
Risk
58
Elevated Risk
Momentum
35
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
Day range
Current $21.6509
52-week range
Current $21.6509
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 132.01M USD | 168.58M USD | 70.36M USD | 26.25M USD | 16.31M USD |
| Selling, general, and administrative | 38.6M USD | 23.82M USD | 14.3M USD | 5.23M USD | 2.42M USD |
| Operating expenses | 170.6M USD | 192.4M USD | 84.66M USD | 31.48M USD | 18.73M USD |
| Interest income | 15.95M USD | 14.59M USD | 12.76M USD | 1.68M USD | — |
| Interest expense | — | — | — | 1.68M USD | 27K USD |
| Depreciation and amortization | 59K USD | 43K USD | — | — | — |
| Operating income | −170.6M USD | −192.4M USD | −84.66M USD | −31.48M USD | −18.73M USD |
| Net income | −154.65M USD | −177.81M USD | −71.9M USD | −29.8M USD | −19.41M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$43.20
99.53% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI50.52M0.00%2.3T USD0.03%$379.13-0.50%
iShares Russell 2000 ETFIWM35.5M0.05%78.56B USD0.19%$275.61-0.75%
State Street SPDR S&P Biotech ETFXBI33.35M0.33%10.08B USD0.35%$146.63-2.40%
Vanguard Extended Market ETFVXF18.89M0.02%95.4B USD0.05%$231.8-0.72%
iShares Russell 2000 Growth ETFIWO12.66M0.09%14.25B USD0.24%$351.12-1.20%
iShares Biotechnology ETFIBB10.13M0.10%10.4B USD0.44%$197.8-2.72%
Vanguard Russell 2000 ETFVTWO8.47M0.05%18B USD0.06%$111.3-0.81%
Schwab U.S. Small-Cap ETFSCHA7.61M0.04%21.7B USD0.03%$32.395-0.66%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
